Mengxian Tu

420 total citations
8 papers, 225 citations indexed

About

Mengxian Tu is a scholar working on Molecular Biology, Cancer Research and Pathology and Forensic Medicine. According to data from OpenAlex, Mengxian Tu has authored 8 papers receiving a total of 225 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 4 papers in Cancer Research and 3 papers in Pathology and Forensic Medicine. Recurrent topics in Mengxian Tu's work include Cancer Mechanisms and Therapy (3 papers), MicroRNA in disease regulation (3 papers) and RNA modifications and cancer (2 papers). Mengxian Tu is often cited by papers focused on Cancer Mechanisms and Therapy (3 papers), MicroRNA in disease regulation (3 papers) and RNA modifications and cancer (2 papers). Mengxian Tu collaborates with scholars based in China, United States and Sweden. Mengxian Tu's co-authors include Chen Qu, Jian Hong, Rongcheng Luo, Hui Yuan, Zike Yang, Xinyi Wang, Mingyu Liu, Zelong Lin, Lu He and Nan Yao and has published in prestigious journals such as American Journal Of Pathology, Cell Death and Disease and Cancer Science.

In The Last Decade

Mengxian Tu

7 papers receiving 224 citations

Peers

Mengxian Tu
Comparison fields: 5 of 47
  • Molecular Biology 116
  • Cancer Research 84
  • Oncology 46
  • Epidemiology 45
  • Surgery 42
Replace Shaohan Wu with:
Shaohan Wu China
Fangfang Bu China
Yichuan Yuan China
Vanessa Rüsseler Germany
Mara Persano Italy
Xianguo Zhou China
Thi Bich Uyen Le Singapore
Huita Wu China
Fenglin Zang China
Shaohan Wu China View profile →
Citations per field, relative to Mengxian Tu
Mengxian Tu · 1×
Citations per year, relative to Mengxian Tu
Mengxian Tu · 1×

Countries citing papers authored by Mengxian Tu

Since Specialization
Citations

This map shows the geographic impact of Mengxian Tu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mengxian Tu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mengxian Tu more than expected).

Fields of papers citing papers by Mengxian Tu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mengxian Tu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mengxian Tu. The network helps show where Mengxian Tu may publish in the future.

Co-authorship network of co-authors of Mengxian Tu

This figure shows the co-authorship network connecting the top 25 collaborators of Mengxian Tu. A scholar is included among the top collaborators of Mengxian Tu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mengxian Tu. Mengxian Tu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
# Work Indexed citations
1 0
2 16
3 28
4 20
5 46
6 50
7
RCE1 deficiency enhances invasion via the promotion of epithelial-mesenchymal transition and predicts poor prognosis in hepatocellular carcinoma.
5
8 60

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026